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responsible for the proliferation of 
Cyld-deficient keratinocytes can 
be examined in Bcl-3-deficient 
mice following TPA and UV stimu-
lation. The authors already indi-
cate such a possibility by showing 
that the depletion of Bcl-3 by small 
interfering RNA reduced cyclin D1 
promoter activation induced by 
TPA and reversed the increased 
proliferation rate of Cyld-deficient 
keratinocytes.
Interestingly, a recent report by 
Reiley et al. (2006) describes a new 
regulatory role for CYLD in T cell 
receptor (TCR) signaling. Cyld-defi-
cient mice are impaired in thymocyte 
development due to aberrations in 
the transition of double-positive to 
single-positive T cells. Contrary to 
the finding in keratinocytes, there are 
no defects in TNF-receptor-induced 
NF-κB signaling in bone-marrow-
derived macrophages of Cyld-defi-
cient mice. The fact that there are 
differences in CYLD function in thy-
mocytes and keratinocytes points to 
receptor-specific and cell-type-spe-
cific functions of CYLD. The regula-
tion of CYLD deubiquitinating activity, 
which is not completely understood, 
awaits further experimental confirma-
tion in distinct cell types. At the same 
time, the understanding of keratino-
cyte-specific signaling mediated by 
CYLD provides a greater opportu-
nity to develop therapeutic agents 
for cylindromatosis. Potential agents 
include nonsteroidal anti-inflamma-
tory drugs (NSAIDs) such as aspirin 
and natural compounds (e.g., ginseng 
extract and green-tea extract), all of 
which can inhibit activation of NF-κB. 
These anti-inflammatory agents and 
CYLD have a similar effect on NF-κB 
signaling, even though they act on 
different targets in the pathway. Topi-
cal application of aspirin has already 
entered clinical trials for the treatment 
of cylindromatosis. It is worth testing 
whether aspirin’s efficacy in treating 
cylindromatosis depends on interfer-
ing with the Bcl-3 pathway as well. 
This study and the excitement in the 
field of NF-κB and cancer pathogen-
esis promise to foster the design of 
better therapeutics for cylindromato-
sis patients.
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In this issue of Cell, Lim et al. (2006) describe a protein-protein interaction network 
for inherited human ataxias, a group of diseases characterized by degeneration of 
cerebellar Purkinje cells. This protein interactome shows that the cerebellar ataxias not 
only share clinical and pathological characteristics but also have proteins, processes, 
and pathways in common.For many proteins associated with 
disease, their precise cellular func-
tion and their role in disease patho-
genesis remain unclear. One strat-egy to gain insight into the function 
of these proteins is to use the tools 
of systems biology to establish their 
connectivity in protein-protein inter-Cell 125action networks. In this issue of Cell, 
Huda Zoghbi and colleagues report 
a protein-protein interaction network 
for the human cerebellar ataxias , May 19, 2006 ©2006 Elsevier Inc. 645
(Lim et al., 2006). This study shows 
that many proteins associated with 
ataxias share common interacting 
protein partners. The results pro-
spectively identify new candidate 
genes for inherited ataxias.
The Lim et al. study was motivated 
by the observation that although 
several inherited cerebellar ataxias 
share clinical and pathological fea-
tures, they are caused by diverse 
mutations in unrelated genes. There 
are two groups of hereditary ataxias 
(Taroni and DiDonato, 2004). Reces-
sive ataxias are caused by mutations 
that lead to a loss of protein function. 
In contrast, most dominant ataxias 
are caused by an expansion of CAG 
triplet repeats in the coding region of 
disease genes, resulting in produc-
tion of a protein with an abnormal 
polyglutamine (polyQ) expansion. In 
their yeast two-hybrid screen, Lim 
et al. (2006) used human proteins 
from three categories as bait: pro-
teins that when mutated are directly 
involved in ataxias, proteins that 
interact with ataxia-causing proteins, 
and paralogs of such proteins. The 
screen revealed 770 protein-protein 
interactions that were subsequently 
assembled into a network along with 
relevant protein-protein interactions 
curated from the literature. Strik-
ingly, this protein-protein interaction 
network is markedly different from a 
control network that was assembled 
using a similar number of disease 
proteins from a group of disorders 
with diverse phenotypes. The ataxia 
interactome network is enriched 
for proteins involved in processes 
thought to be important in several 
inherited ataxias. These processes 
include DNA repair and maintenance, 
transcription, RNA processing, and 
protein quality control and recycling.
Zoghbi and colleagues have iden-
tified connections between different 
proteins that, when mutated, cause 
ataxias. In addition to dominant 
ataxias, polyQ expansions are also 
found in noncerebellar disorders 
such as Huntington’s disease (HD). 
One question that arises is whether 
we can expand some of the protein-
protein interactions identified in the 
ataxia network to help identify the 646 Cell 125, May 19, 2006 ©2006 Elsevinteracting partners of other polyQ-
containing proteins. Indeed, the 
observation that the same mutation 
in different proteins can cause neuro-
nal death suggests that some patho-
genic mechanisms could be shared 
by these disorders. In particular, in 
both HD and the cerebellar ataxias 
the polyQ-containing proteins must 
be localized to the nucleus for the 
pathogenic process to occur, and 
in both cases a dysregulation of the 
transcriptional machinery is involved. 
Interestingly, if one compares the 
previously published interactome 
for huntingtin (which is the protein 
mutated in Huntington’s disease) 
(Goehler et al., 2004) with the new 
ataxia interactome (Lim et al., 2006), 
several nuclear proteins appear 
repeatedly, including the TATA bind-
ing protein (TBP) and p53, which are 
both important transcriptional regu-
lators. PolyQ expansions in TBP are 
associated with the spinocerebel-
lar ataxia, SCA17. However, some 
abnormal polyQ expansions in TBP 
are also found in patients clinically 
diagnosed with HD but who do not 
have the polyQ expansion in the hunt-
ingtin protein (Stevanin et al., 2003). 
This observation further supports the 
notion that mutation in functionally 
related proteins may generate similar 
phenotypes in patients.
Given what is shared among these 
disorders, what makes them dif-
ferent from one another? The com-
monly accepted theory for the polyQ 
diseases is that the polyQ expan-
sion in different proteins leads to the 
death of a different subset of neurons 
depending on the disease. However, 
when carefully analyzed, juvenile 
HD patients with highly expanded 
stretches of polyQ in the hunting-
tin protein also develop ataxia and 
show cerebellar degeneration. This 
suggests that when the number 
of glutamine repeats goes above 
a certain threshold, the specificity 
between these disorders is lost. Per-
haps above this threshold the pro-
tein-protein interactions become less 
specific, which leads to interactions 
that are detrimental to the survival of 
all neurons not just a specific subset. 
Below this threshold, the pathology ier Inc.of each disease may be driven by 
protein-protein interactions specific 
to the context of the disease protein, 
thereby leading to cell death of a 
particular neuronal type. In support 
of this idea, posttranslational modi-
fications (such as phosphorylation) 
that are outside the polyQ stretch in 
some of these proteins are sufficient 
to abrogate their toxicity. This finding 
strengthens the rationale underpin-
ning Lim et al.’s protein-protein inter-
action study and raises the question 
of whether short protein fragments 
with large polyQ repeats should be 
used to model these diseases.
Lim et al. (2006) demonstrate 
that genes and proteins causing 
the same or related diseases may 
interact with or be part of the same 
pathway. This may also be true of 
neurodegenerative disorders that 
affect other brain regions, such as 
Parkinson’s disease (PD), which 
stems from the loss of dopaminer-
gic neurons in the substantia nigra. 
Mutations in several genes respon-
sible for sporadic and familial forms 
of PD result in similar phenotypes. 
The first and best studied are the 
genes for α-synuclein and parkin. 
Mutations in α-synuclein and par-
kin lead to dominant and recessive 
forms of PD, respectively. Interest-
ingly, there is a clear connection 
between the two proteins. Parkin 
ubiquitinates the α-synuclein-inter-
acting protein synphilin-1 and/or a 
glycosylated form of α-synuclein, 
thus participating in the formation 
of Lewy bodies, the protein aggre-
gates frequently seen in the brains 
of PD patients (Chung et al., 2001; 
Shimura et al., 2001). More recently, 
parkin has been shown to interact 
with the leucine-rich repeat kinase-2 
(LRRK2), a kinase that is mutated in 
an autosomal dominant form of PD 
(Smith et al., 2005). From these two 
examples, it appears that mutations 
in proteins belonging to the same 
functional network may be respon-
sible for diseases that share similar 
clinical presentations. It is therefore 
tempting to speculate that building 
a protein-protein interaction net-
work from proteins that cause PD 
may help to identify mutations that 
are responsible for other sporadic 
and familial forms of the disease 
and could lead to the identification 
of new susceptibility genes.
Several types of protein-protein 
interaction maps have been devel-
oped. These include specific interac-
tion networks, such as the ataxia net-
work presented by Lim et al. (2006), 
which generate a huge number of 
gene modifier candidates that may 
participate in or regulate patho-
genic processes. Other networks 
have described interactions across 
the entire proteome in model organ-
isms such as yeast, Drosophila, and 
Caenorhabditis elegans. Approaches 
to systematically map human protein 
interactions have also been under-
taken (Rual et al., 2005; Stelzl et al., 
2005). These networks are certainly 
not independent and should be con-
sidered together as they will contrib-
ute in a complementary manner to Validating therapeutic targets is an 
inherently difficult undertaking. The 
sheer number of potential drug tar-
gets in the postgenomic era makes 
validation the rate-limiting step in 
drug development (Lindsay, 2003). 
Not surprisingly, many more thera-
peutic candidates fail because of a 
lack of efficacy rather than because 
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the PI3 kinase (PI3-K) family u
PI3-K isoform, has a critical ro
al. (2006) show that blocking a
molecule inhibitor limits the grunderstanding the mechanisms that 
control cellular behavior in develop-
ment and disease. Indeed, thousands 
of interactions have been described, 
and now the challenge is to conduct 
comparative analysis of these inter-
actomes to organize these data. 
We also need to further address the 
dynamics of these systems. Thus, it 
will be critical to determine when and 
where these interactions occur and 
how they are regulated both within a 
given cell and in the context of whole 
tissues.
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